BioWorld

Jan. 14, 2002

View Archived Issues

IGEN Wins $505M From Roche In Court; Roche Plans To Appeal

Same Gene Inflicts Both Axonal And Demyelinating Versions Of Charcot-Marie-Tooth Neuropathy

Antigenics Raises $60M From Shelf For Oncophage Trials

Novo Ends Deal With Flamel, Flamel Signs Deal With Servier

Other News To Note

U.S. Patent Disclosures

Dendreon Falls On Provenge Phase III Interim Analysis Results

Poor interim statistical analysis of a Phase III trial of Provenge in prostate cancer patients caused Seattle-based Dendreon Corp.'s stock to dive Friday. Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 29, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...